News | FFR Technologies | May 15, 2020

OCT May be Able to Show FFR Without Need for Pressurewire

Cutting-edge imaging may provide insight into the functional significance of a stenosis

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.


May 15, 2020 – A late-breaking study aimed to evaluate whether optical coherence tomography (OCT) can predict fractional flow reserve (FFR) values and assess if OCT parameters may predict clinical outcome in patients with negative FFR. The study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions Virtual Conference.

OCT imaging offers high-resolution intracoronary imaging technique used to characterize plaque morphology and to guide optimization of percutaneous coronary intervention (PCI). It also might provide some insights into the physiological, functional significance of a stenosis.

“The idea of predicting hemodynamic relevance of coronary lesions from imaging is extremely appealing. In this collaborative study we sought to investigate if OCT parameters may help predicting the presence of hemodynamically significant stenoses among angiographically-intermediate coronary lesions (AICL)," said Rocco Vergallo, M.D., Ph.D., Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy. “We put together data collected from different studies so that we have been able to analyze individual data of about 500 patients.”

The research team, under the leadership of Francesco Burzotta, M.D., lead investigator, Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy, designed a multicenter, international, study using individual patient's level data pooled analysis. Stable or unstable patients who underwent both FFR and OCT of the same coronary lesion were enrolled. Primary outcome measures were OCT parameters predicting an FFR <0.80, including mean lumen area (MLA), percentage area stenosis (%AS), and presence of plaque thrombus/rupture. =

Secondary outcome was the incidence of major adverse cardiac events (MACE) in patients not undergoing revascularization based on negative FFR (≥0.80). MACEs were defined as the composite of cardiac death, spontaneous myocardial infarction (MI) and target lesion revascularization.

A total of 502 coronary lesions in 489 patients were included. A significant correlation was observed between OCT-MLA and FFR values (R=0.525, p<0.001), and between OCT-%AS and FFR values (R=-0.482, p<0.001), while plaque thrombus/rupture did not differ significantly. At ROC analysis, an OCT-MLA <2.0 mm2 showed a good discriminative power to predict an FFR<0.80 (AUC 0.80), as well as an OCT %AS >73% (AUC 0.73). When considering proximal coronary segments only, the best OCT cut-off values predicting an FFR<0.80 were MLA <3.1 mm2 (AUC 0.82), and %AS >61% (AUC 0.84). Among 105 patients who had not undergone revascularization based on negative FFR and had completed the clinical follow up, 11 (10.5%) had MACE. Median follow-up time was 6 years (IQR: 2.3-8.3). Patients with MLA <2 mm2 showed a non-significantly higher incidence of MACE than those with MLA ≥2 mm2 (16.7% vs. 9.2%, p=0.139).

“These findings are important because they may allow interventional cardiologists to gather both data on plaque morphology/lumen dimension and indirect information on the functional significance of a stenosis by using an imaging catheter only, without the need for an additional pressure wire,” Vergallo continued. “This would, in turn, reduce both patient risk and healthcare expenses.”

For more information: www.scai.org

 

Find more SCAI news and video

Related Content

News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
Subscribe Now